Icotrokinra clinical trials
Also written JNJ-77242113 and PN-21235,.
How each study uses icotrokinra is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the icotrokinra studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 17 Mar 2026 · ICOTYDE · NDA 220149 (FDA, Drugs@FDA)
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
13 studies that test it; most in 2023 (4)
| Year | Studies |
|---|---|
| 2021 | 1 |
| 2022 | 3 |
| 2023 | 4 |
| 2024 | 1 |
| 2025 | 4 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 13 · Other 0
Janssen Research & Development, LLC (11) · Janssen Pharmaceutical K.K. (2)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1, 1 in phase 3
Studies that test icotrokinra, phase 3 first.
- Feb 2027A Study to Evaluate the Efficacy and Safety of Icotrokinra (JNJ-77242113) in Biologic-experienced and Biologic-naive Participants With Active Psoriatic ArthritisPhase 3 · Janssen Research & Development, LLC
Studies
Open first, then newest update. How each study uses icotrokinra is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 13
- A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's DiseaseRecruitingPhase 2/3Janssen Research & Development, LLCNCT07196722Written as Icotrokinra
- A Study of JNJ-77242113 in Adolescent and Adult Participants With Moderate to Severe Plaque PsoriasisActive, not recruitingPhase 3Janssen Research & Development, LLCNCT06095115Written as JNJ-77242113
- A Study to Evaluate the Efficacy and Safety of Icotrokinra (JNJ-77242113) in Biologic-experienced and Biologic-naive Participants With Active Psoriatic ArthritisActive, not recruitingPhase 3Janssen Research & Development, LLCNCT06807424Written as Icotrokinra
- A Study of JNJ-77242113 for the Treatment of Participants With Plaque Psoriasis Involving Special Areas (Scalp, Genital, and/or Palms of the Hands and the Soles of the Feet)Active, not recruitingPhase 3Janssen Research & Development, LLCNCT06095102Written as JNJ-77242113
- A Study to Evaluate the Efficacy and Safety of JNJ-77242113 (Icotrokinra) in Biologic-naïve Participants With Active Psoriatic ArthritisActive, not recruitingPhase 3Janssen Research & Development, LLCNCT06878404Written as Icotrokinra
- A Protocol of Icotrokinra Therapy in Adult and Adolescent Participants With Moderately to Severely Active Ulcerative ColitisActive, not recruitingPhase 3Janssen Research & Development, LLCNCT07196748Written as Icotrokinra
- A Study of JNJ-77242113 for the Treatment of Participants With Generalized Pustular Psoriasis or Erythrodermic PsoriasisActive, not recruitingPhase 3Janssen Pharmaceutical K.K.NCT06295692Written as JNJ-77242113
- A Long-term Extension Study of JNJ-77242113 in Participants With Moderate-to-Severe Plaque PsoriasisCompletedPhase 2Janssen Research & Development, LLCNCT05364554Written as JNJ-77242113
- A Study of JNJ-77242113 for the Treatment of Moderate-to-Severe Plaque PsoriasisCompletedPhase 2Janssen Research & Development, LLCNCT05357755Written as JNJ-77242113
- A Study of JNJ-77242113 in Participants With Moderately to Severely Active Ulcerative ColitisCompletedPhase 2Janssen Research & Development, LLCNCT06049017Written as JNJ-77242113
- A Study of JNJ-77242113 in Participants With Moderate-to-severe Plaque PsoriasisCompletedPhase 2Janssen Research & Development, LLCNCT05223868Written as JNJ-77242113
- A Study of JNJ-77242113 in Healthy Japanese and Chinese ParticipantsCompletedPhase 1Janssen Pharmaceutical K.K.NCT05062200Written as JNJ-77242113
- A Study of JNJ-77242113 Following Oral Administration in Healthy Chinese Adult ParticipantsCompletedPhase 1Janssen Research & Development, LLCNCT05703841Written as JNJ-77242113
Given beside what is tested · 3 — icotrokinra is usual care or a partner of the new treatment
- A Study of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis (ICONIC-ADVANCE 2)Active, not recruitingPhase 3Janssen Research & Development, LLCNCT06220604Written as JNJ-77242113
- A Study of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque PsoriasisActive, not recruitingPhase 3Janssen Research & Development, LLCNCT06143878Written as JNJ-77242113
- A Study to Assess Efficacy and Safety of JNJ-77242113 Compared to Placebo and Ustekinumab in Participants With Moderate to Severe Plaque PsoriasisActive, not recruitingPhase 3Janssen Research & Development, LLCNCT06934226Written as JNJ-77242113
Codes
What other systems call icotrokinra · ClinicalTrials.gg INT002191
- MeSH (NLM) C000732017icotrokinraOne source NLM
- UNII (FDA) MUW8FP7HNZICOTROKINRAConfirmed FDA, NLM, Wikidata
- Wikidata Q131418207icotrokinraConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C206920IcotrokinraOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000732017 | icotrokinra | One source NLM |
| UNII (FDA) | MUW8FP7HNZ | ICOTROKINRA | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q131418207 | icotrokinra | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C206920 | Icotrokinra | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.